Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2014 December;105(6 Suppl 3) > Minerva Medica 2014 December;105(6 Suppl 3):9-13

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

  PNEUMOLAB PROCEEDINGS


Minerva Medica 2014 December;105(6 Suppl 3):9-13

language: English

Multi-platform lung tumors profiling identifies actionable targets and unveils series of uncommon/rare diseases

Stella G. M.

Laboratory of Biochemistry and Genetics Pulmonology Unit, Department of Molecular Medicine, University and Fondazione IRCCS, Policlinico San Matteo di Pavia, Pavia, Italy


FULL TEXT  


Lung cancer is characterized by a number of genetic alterations, of which a proportion is still unknown. Nevertheless numerous pathogenetically important driver changes have been already been detected in a substantial fraction of patients and translated into a system to improve detection and outcome of the disease. In this scenario, the Lung Cancer Mutation Consortium developed an ambitious project aimed to perform on large scale the molecular profile of lung adenocarcinoma in order to identify actionable targets. The review analyses the paper - recently published showing study findings- taking into account if the car and not the driver matters in lung cancer precision management.

top of page

Publication History

Cite this article as

Corresponding author e-mail

G.Stella@smatteo.pv.it